Adjuvant Chemotherapy Versus Concurrent Chemoradiotherapy for Surgically Treated T1b Uterine Cervical Cancer: A Propensity Score Matched Analysis of the JSOG Nationwide Data

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2024 Dec 11

PMID 39663326

Authors

Yusuke Tanaka

Shota Higami

Tomomi Ishii

Yasuhiko Shiki

Yutaka Ueda

Tadashi Kimura

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this study was to assess the effect of postoperative chemotherapy on the survival of surgically treated patients with T1b uterine cervical cancer.

Methods: Overall, 1687 patients with T1b cervical cancer who received concurrent chemoradiotherapy (CCRT) or chemotherapy as postoperative adjuvant therapy were retrospectively analyzed using the Japan Society of Obstetrics and Gynecology cancer registry program data from 2015 to 2016. After propensity score matching, overall survival (OS) was compared between 643 patients treated with CCRT and 643 patients treated with chemotherapy.

Results: OS was significantly higher in the chemotherapy group than in the CCRT group (hazard ratio [HR] 0.653, 95% confidence interval [CI] 0.448 - 0.953; p = 0.026). In the subgroup analysis, patients with squamous histology and large tumor size (>4 cm) and without lymph node metastasis can benefit from chemotherapy in terms of OS (HR 0.53, 95% CI 0.29-0.95; HR 0.49, 95% CI 0.25-0.95; and HR 0.54, 95% CI 0.33-0.88, respectively).

Conclusion: Patients with cervical cancer with squamous histology, large tumor size and negative lymph node metastasis can benefit from postoperative chemotherapy in terms of survival. Tumor characteristics could be associated with the effect of postoperative adjuvant chemotherapy on survival.

Citing Articles

Circulating Micro-RNA as a Predictive Biomarker for Radiation Response in Pancreas Cancer.

Etherington M, Karakousis G Ann Surg Oncol. 2024; 32(2):629-631.

PMID: 39546102 DOI: 10.1245/s10434-024-16445-9.

References

Bhatla N, Aoki D, Sharma D, Sankaranarayanan R . Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet. 2021; 155 Suppl 1:28-44. PMC: 9298213. DOI: 10.1002/ijgo.13865. View

Koh W, Abu-Rustum N, Bean S, Bradley K, Campos S, Cho K . Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 17(1):64-84. DOI: 10.6004/jnccn.2019.0001. View

Frumovitz M, Sun C, Schover L, Munsell M, Jhingran A, Wharton J . Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol. 2005; 23(30):7428-36. DOI: 10.1200/JCO.2004.00.3996. View

Falcetta F, Medeiros L, Edelweiss M, Pohlmann P, Stein A, Rosa D . Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database Syst Rev. 2016; 11:CD005342. PMC: 6473195. DOI: 10.1002/14651858.CD005342.pub4. View

Takekuma M, Kasamatsu Y, Kado N, Kuji S, Tanaka A, Takahashi N . Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomy. Int J Clin Oncol. 2016; 21(4):741-747. DOI: 10.1007/s10147-016-0955-3. View

Matsuo K, Shimada M, Aoki Y, Sakamoto M, Takeshima N, Fujiwara H . Comparison of adjuvant therapy for node-positive clinical stage IB-IIB cervical cancer: Systemic chemotherapy versus pelvic irradiation. Int J Cancer. 2017; 141(5):1042-1051. PMC: 7526701. DOI: 10.1002/ijc.30793. View

Kagabu M, Nagasawa T, Tatsuki S, Fukagawa Y, Tomabechi H, Takatori E . Comparison of Postoperative Adjuvant Chemotherapy and Concurrent Chemoradiotherapy for FIGO2018 Stage IIIC1 Cervical Cancer: A Retrospective Study. Medicina (Kaunas). 2021; 57(6). PMC: 8227555. DOI: 10.3390/medicina57060548. View

Matsuo K, Nusbaum D, Matsuzaki S, Klar M, Shimada M, Takekuma M . Utilization and outcomes of adjuvant systemic chemotherapy alone in high risk, early stage cervical cancer in the United States. Int J Gynecol Cancer. 2021; 31(7):991-1000. DOI: 10.1136/ijgc-2021-002655. View

Zhang H, Yu R, Zhang L, Wang R, Xiao L . Chemotherapy versus chemoradiotherapy for FIGO stages IB1 and IIA1 cervical squamous cancer patients with lymphovascular space invasion: a retrospective study. BMC Cancer. 2022; 22(1):202. PMC: 8864837. DOI: 10.1186/s12885-022-09309-6. View

10.

Bujnak A, Tewari K . Should adjuvant chemotherapy be formally studied among patients found to have pelvic lymph node metastases following radical hysterectomy with lymphadenectomy for early-stage cervical cancer?. J Gynecol Oncol. 2021; 32(4):e62. PMC: 8192234. DOI: 10.3802/jgo.2021.32.e62. View

11.

Ikeda M, Shida M, Shigeta S, Nagase S, Takahashi F, Yamagami W . The trend and outcome of postsurgical therapy for high-risk early-stage cervical cancer with lymph node metastasis in Japan: a report from the Japan Society of Gynecologic Oncology (JSGO) guidelines evaluation committee. J Gynecol Oncol. 2021; 32(3):e44. PMC: 8039172. DOI: 10.3802/jgo.2021.32.e44. View

12.

Ebina Y, Yaegashi N, Katabuchi H, Nagase S, Udagawa Y, Hachisuga T . Japan Society of Gynecologic Oncology guidelines 2011 for the treatment of uterine cervical cancer. Int J Clin Oncol. 2015; 20(2):240-8. DOI: 10.1007/s10147-015-0806-7. View

13.

Kanda Y . Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2012; 48(3):452-8. PMC: 3590441. DOI: 10.1038/bmt.2012.244. View

14.

Peters 3rd W, Liu P, Barrett 2nd R, STOCK R, Monk B, Berek J . Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000; 18(8):1606-13. DOI: 10.1200/JCO.2000.18.8.1606. View

15.

Lahousen M, Haas J, Pickel H, Hackl A, Kurz C, Ogris H . Chemotherapy versus radiotherapy versus observation for high-risk cervical carcinoma after radical hysterectomy: A randomized, prospective, multicenter trial. Gynecol Oncol. 1999; 73(2):196-201. DOI: 10.1006/gyno.1999.5343. View

16.

Weng D, Xiong H, Zhu C, Wan X, Chen Y, Wang X . Adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer: a randomized, non-inferiority, multicenter trial. Front Med. 2022; 17(1):93-104. PMC: 9686219. DOI: 10.1007/s11684-021-0892-z. View

17.

Furusawa A, Takekuma M, Mori K, Usami T, Kondo E, Nishio S . A randomized phase III trial of adjuvant chemotherapy versus concurrent chemoradiotherapy for postoperative cervical cancer: Japanese Gynecologic Oncology Group study (JGOG1082). Int J Gynecol Cancer. 2021; 31(4):623-626. DOI: 10.1136/ijgc-2020-002344. View